Vaxcyte soars on positive data from Phase I/II study of VAX-24

24 October 2022

US vaccine developer Vaxcyte (Nasdaq: PCVX) roared up 79% to $20.58 in pre-market trading today, as the company revealed encouraging early-stage results with its investigational pneumococcal vaccine.

Top-line results from the Phase I/II clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24, the company’s investigational 24-valent pneumococcal conjugate vaccine (PCV), in healthy adults aged 18-64 showed the vaccine met the primary safety and tolerability objectives, demonstrating a safety profile similar to Prevnar 20 (PCV20) for all doses studied.

California-based Vaxcyte claims that VAX-24 is among the broadest spectrum PCVs in development and one of the most complex biologics ever developed. The 24 serotypes included in VAX-24 cover a significant portion of the IPD currently in circulation and are associated with high case-fatality rates, antibiotic resistance and meningitis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK